BGV — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.
BiotechDigital HealthHealthtechMedical DevicesMunich, DE
Rafiq Hasan(CEO and Managing Director)inMuhammad Ali Memon(Chief Medical Officer)in
Co-investorsCambridge Innovation CapitalHadean VenturesSeroba Life SciencesBioGeneration VenturesForbionGimv+1 more
EverestLabs builds RecycleOS, an AI-powered operating system for recycling plants that uses computer vision, AI, and robotics to identify and sort recyclable materials in Material Recovery Facilities (MRFs).
AI & Machine LearningCircular EconomyClimate TechImpact & Social GoodRoboticsFremont, US
R Paul Singh(CEO)JD Ambati(Founder/Chief Strategy Officer)in
Co-investorsSierra VenturesTransLink CapitalUnanimous CapitalXplorer CapitalBenhamou Global VenturesHike Ventures+1 more
Enterprise Software
Co-investorsBonfire VenturesCommerce VenturesConexus Venture CapitalCRV (Charles River Ventures)Emery CapitalFinTech Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.